April 2008
M	T	W	T	F	S	S
« Mar		May »
1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Medical Articles 4/25

Posted by rob on April 25, 2008 under Uncategorized | Be the First to Comment

AML1 and Evi1: coconspirators in MDS/AML?

Solution
conformations and dynamics of ABL kinase inhibitor complexes determined
by NMR substantiate the different binding modes of imatinib/nilotinib
and dasatinib.

Unrelated
cord blood transplantation for severe congenital neutropenia: Report of
two cases with very different transplant courses.

in vitro Biological Evaluation of Folate-Functionalized Block Copolymer Micelles for Selective Anti-Cancer Drug Delivery.

Bullous
sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic
myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib:
interphase cytogenetic detection of BCR-ABL- positive lesional cells.

White Flower

Posted by rob on April 24, 2008 under Uncategorized | Be the First to Comment

by Clickr_Clickr

Medical Articles 4/24

Posted by rob on under Uncategorized | Be the First to Comment

Resveratrol
induces apoptosis in K562 (chronic myelogenous leukemia) cells by
targeting a key survival protein, heat shock protein 70.

Nilotinib (Tasigna) for CML.

Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.

ABT-737
is a useful component of combinatory chemotherapies for chronic myeloid
leukaemias with diverse drug-resistance mechanisms.

Medical Articles 4/22

Posted by rob on April 22, 2008 under Uncategorized | Be the First to Comment

A
dual colour dual fusion fluorescence in situ hybridisation study on the
genesis of complex variant translocations in chronic myelogenous
leukaemia.

Identification
of an epitope derived from CML66, a novel tumor-associated antigen
expressed broadly in human leukemia, recognized by human leukocyte
antigen-A*2402-restricted cytotoxic T lymphocytes.

[Expression of telomere binding factor 2 (TRF2) on leukemia cell lines and primary leukemia cells.]

Medical Articles 4/21

Posted by rob on April 21, 2008 under Uncategorized | Be the First to Comment

METABOLISM AND DISPOSITION OF DASATINIB AFTER ORAL ADMINISTRATION TO HUMANS.

An
intron-derived insertion/truncation mutation in the BCR-ABL kinase
domain in chronic myeloid leukemia patients undergoing kinase inhibitor
therapy.

Cyclic
nucleotide-regulated proliferation and differentiation vary in human
hematopoietic progenitor cells derived from healthy persons, tumor
patients, and chronic myelocytic leukemia patients.

Medical Articles 4/19

Posted by rob on April 19, 2008 under Uncategorized | Be the First to Comment

CD34+CD38+CD19+
as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with
self-renewal capacity in human B-precursor ALL.

Disruption
of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit
Bcr-Abl-positive human leukemic blasts by novobiocin.

Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia.

New drugs: nebivolol hydrochloride, nilotinib, and sapropterin dihydrochloride.

Medical Articles 4/17

Posted by rob on April 17, 2008 under Uncategorized | Be the First to Comment

Dose-finding
study of imatinib in combination with intravenous cytarabine:
feasibility in newly diagnosed patients with chronic myeloid leukemia.

BMS-214662
potently induces apoptosis of chronic myeloid leukemia stem and
progenitor cells and synergizes with tyrosine kinase inhibitors.

Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.

Long-term imatinib therapy promotes bone formation in CML patients.

Medical Articles 4/14

Posted by rob on April 14, 2008 under Uncategorized | Be the First to Comment

A New DNA-Based Test for Detection of Nucleophosmin Exon 12 Mutations by Capillary Electrophoresis.

Role
of p21(WAF1/CIP1) as an attenuator of both proliferative and
drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic
cells.

Basic
fibroblast growth factor inhibits p38-mediated cell differentiation and
growth inhibition by activin A but not by histone deacetylase
inhibitors in CML cells.

Medical Articles 4/11

Posted by rob on April 11, 2008 under Uncategorized | Be the First to Comment

Immunotherapeutic approaches in chronic myelogenous leukemia.

BCR/ABL, DNA damage and DNA repair: implications for new treatment concepts.

Successful
autologous stem cell collection in patients with chronic myeloid
leukemia in complete cytogenetic response, with quantitative
measurement of BCR-ABL expression in blood, marrow, and apheresis
products.

(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.

Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia.

Imatinib mesylate induced immune thrombocytopenia.

Philadelphia
chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical
correlates and effect on imatinib mesylate treatment outcome.

Medical Articles 4/6

Posted by rob on April 6, 2008 under Uncategorized | Be the First to Comment

Effective
killing of Gleevec-resistant CML cells with T315I mutation by a natural
compound PEITC through redox-mediated mechanism.

KIS induces proliferation and the cell cycle progression through the phosphorylation of p27(Kip1) in leukemia cells.

Effects
of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6
substrate, in Chinese patients with chronic myelogenous leukaemia.

Tumor-specific cytotoxicity and type of cell death induced by beta-cyclodextrin benzaldehyde inclusion compound.

Medical Articles 4/5

Posted by rob on April 5, 2008 under Uncategorized | Be the First to Comment

Effective
killing of Gleevec-resistant CML cells with T315I mutation by a natural
compound PEITC through redox-mediated mechanism.

KIS induces proliferation and the cell cycle progression through the phosphorylation of p27(Kip1) in leukemia cells.

Effects
of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6
substrate, in Chinese patients with chronic myelogenous leukaemia.

Tumor-specific cytotoxicity and type of cell death induced by beta-cyclodextrin benzaldehyde inclusion compound.

Medical Articles 4/2

Posted by rob on April 2, 2008 under Uncategorized | Be the First to Comment

Homoharringtonine for the treatment of chronic myelogenous leukemia.

Alterations
in creatine kinase, phosphate and lipid values in patients with chronic
myeloid leukemia during treatment with imatinib.

Monitoring treatment of chronic myeloid leukemia.

Comparison
of bone marrow high mitotic index metaphase fluorescence in situ
hybridization to peripheral blood and bone marrow real time
quantitative polymerase chain reaction on the International Scale for
detecting residual disease in chronic myeloid leukemia.

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.

Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.

Differential
activation of the death receptor pathway in human target cells induced
by cytotoxic T lymphocytes showing different kinetics of killing.

Stem
cell regulation and the development of blast crisis in chronic myeloid
leukemia: Implications for the outcome of Imatinib treatment and
discontinuation.

Medical Articles 4/1

Posted by rob on April 1, 2008 under Uncategorized | Be the First to Comment

Current Approaches to Management of Cerebral Fungal Infection in Pediatric Patients With Hematologic Disorders.

Galangin
increases the cytotoxic activity of imatinib mesylate in
imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia
cells.

Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia.

Archives

Recent Posts

Meta